Japan Law Revisions Allow Medical Cannabis But Tighten Other Restrictions
Epidiolex Phase III Ongoing
After years of discussions, Japan has revised legislation relating to the use of medicines containing cannabinoids, while also officially criminalizing the non-medical use of marijuana. The move may pave the way for easier use of medicines such as Epidiolex, for which a local Phase III trial started in 2022.
You may also be interested in...
After a year of revising and opening up its regulations for new drugs in 2023, Japan is aiming to add more reimbursement pricing premiums for innovative medicines in 2024, while cautiously discussing other detailed revisions to regulations and the pricing system.
Finally responding to pressure from domestic physicians, Japan has started discussions on the possible revision of long-standing regulations to allow the medical use of cannabis products, while putting in place strict measures to prevent illegal use or distribution.
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.